


## (E)-3,4,5-Trimethoxycinnamic acid

<b>Cat. No.:</b>	HY-W050162		
<b>CAS No.:</b>	20329-98-0		
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>14</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	238.24		
<b>Target:</b>	GABA Receptor; 5-HT Receptor		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (419.74 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	4.1974 mL	20.9872 mL	41.9745 mL
	<b>5 mM</b>	0.8395 mL	4.1974 mL	8.3949 mL
	<b>10 mM</b>	0.4197 mL	2.0987 mL	4.1974 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution</li> </ol>			

### BIOLOGICAL ACTIVITY

<b>Description</b>	(E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABA <sub>A</sub> /BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT <sub>2C</sub> and 5-HT <sub>1A</sub> receptor, with IC <sub>50</sub> values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy <sup>[1][2][3]</sup> .
<b>In Vitro</b>	(E)-3,4,5-Trimethoxycinnamic acid (10 μg/mL, 1 h) increases the expressions of GAD <sub>65</sub> and γ-subunit of GABA <sub>A</sub> receptors in

the cerebellar granule cells<sup>[3]</sup>.

(E)-3,4,5-Trimethoxycinnamic acid (0-10 µg/mL, 1 h) shows a significant increase in Cl<sup>-</sup> influx<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Western Blot Analysis<sup>[3]</sup>

Cell Line:	Primary cultured cerebellar granule cells
Concentration:	10 µg/mL
Incubation Time:	1 h
Result:	Increased expression of GAD <sub>65</sub> (glutamic acid decarboxylase) and γ-subunit of GABAA receptors, but did not influence the amounts of α-, β-subunits in the GABAA receptors.

#### Cell Viability Assay<sup>[3]</sup>

Cell Line:	Primary cultured cerebellar granule cells
Concentration:	1, 3, 5, 10 µg/mL
Incubation Time:	1 h
Result:	Produced a significant increase in Cl <sup>-</sup> influx.

#### In Vivo

(E)-3,4,5-Trimethoxycinnamic acid (0-20 mg/kg, IP, once) shows anti-seizure effects<sup>[2]</sup>.

(E)-3,4,5-Trimethoxycinnamic acid (0-10 mg/kg, Orally, once) enhances hypnotic effects in pentobarbital-treated mice<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ault male KunMing-strain mice (18-20 g, maximal electroshock (MES) and pentylenetetrazol (PTZ) models) <sup>[2]</sup>
Dosage:	5, 10 and 20 mg/kg; 10 mL/kg
Administration:	IP, once
Result:	Significantly decreased the incidence of MES-induced THE (tonic hindlimb extension) to 50% and 20% of the value of the vehicle controls at 10 and 20 mg/kg. Decreased the incidence of MES-induced THE to only 80% at 5 mg/kg. Significantly delayed the onset of myoclonic jerks (MJ), and decreased the seizure severity and mortality compared with the vehicle-treated animals in PTZ seizure model. The incidence of generalized clonic convulsions (stage 4) disappeared at doses of both 10 and 20 mg/kg.

Animal Model:	ICR male mice (25-28 g, 10-12 in each group) <sup>[3]</sup>
Dosage:	2, 5 and 10 mg/kg
Administration:	Orally (p.o.), once, 15 min and 1 h prior to pentobarbital injection
Result:	Significantly decreased locomotor activity at 10 mg/kg. Increased NREM and total sleep, but decreased wakefulness.

## REFERENCES

[1]. Zhao Z, et al. Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. Eur J Med Chem. 2019 Jul 1;173:213-227.

---

[2]. Chen CY, et al. 3,4,5-Trimethoxycinnamic acid, one of the constituents of Polygalae Radix exerts anti-seizure effects by modulating GABAergic systems in mice. J Pharmacol Sci. 2016 May;131(1):1-5.

[3]. Lee CI, et al. 3,4,5-Trimethoxycinnamic acid (TMCA), one of the constituents of Polygalae Radix enhances pentobarbital-induced sleeping behaviors via GABAergic systems in mice. Arch Pharm Res. 2013 Oct;36(10):1244-51.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA